« Return to News | Clinical Intelligence

NicOx to appeal FDA rejection

Tuesday, March 1, 2011 08:30 AM

French biotech NicOx said last week it plans to appeal the FDA’s decision to turn down its anti-inflammatory drug naproxcinod for marketing approval, Reuters reported. NicOx made the announcement at its 2010 earnings presentation.

The agency 2010 refusal to approve naproxcinod, once touted by NicOx as a possible competitor to Pfizer's Celebrex, led NicOx to announce a restructuring of its business, cutting its 128-person workforce in half, shuttering its U.S. headquarters and realigning its R&D efforts.

According to Fierce Biotech, NicOx faces an uphill climb. It never got very far in attempting to persuade U.S. regulators that it had developed a safe, non-steroidal anti-inflammatory painkiller. An expert committee voted 16-to-1 last year that it never made a successful case that the therapy, intended to succeed where Celebrex failed, did not raise blood pressure. The FDA formally agreed soon after, suggesting new clinical studies designed to demonstrate the drug's safety and clinical benefit. Regulators have proved time and again that new drugs intended for mass markets must have clearly defined safety profiles. The chances of the agency changing its decision now would appear to be remote.

In a roundup of events included in the company's annual report, NicOx also reported that preclinical results of a drug for neuropathic pain along with a separate therapy for diabetic macular edema looked promising. And it is currently looking for new alliances for each of the programs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.